Suggested remit: To appraise the clinical and cost effectiveness of selpercatinib within its marketing authorisation for treating untreated advanced RET fusion-positive thyroid cancer and untreated advanced RET mutation-positive medullary thyroid cancer.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6132

Provisional Schedule

Draft guidance 01 May 2024 - 23 May 2024
Committee meeting: 2 12 June 2024
Expected publication 21 August 2024

Project Team

Project lead Celia Mayers

Email enquiries

External Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool


Companies sponsors Eli Lilly (selpercatinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups AMEND (Association for Multiple Endocrine Neoplasia Disorders)
  British Thyroid Foundation
  Butterfly Thyroid Cancer Trust
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Comparator companies Bayer (sorafenib) – confidentiality agreement not signed, not participating
  Eisai (lenvatinib)
  Ipsen (cabozantinib)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
10 April 2024 Committee meeting
23 August 2023 Invitation to participate
11 July 2023 - 08 August 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
11 July 2023 In progress. Scoping commenced
16 May 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual